INVESTIGATION OF TOTAL AND FREE PSA LEVELS IN HEMODIALYSIS PATIENTS

Abstract

Objective: In patients with chronic renal failure, hemodialysis administration on serum total and free
prostate-specific antigen (PSA) levels was aimed to investigate.
Materials and Methods: 35 hemodialysis for chronic renal failure as patient group and 35 healthy
subjects as control group who were examined in terms of PSA levels for prostate cancer were included
in the study, conducted between January 2011-March 2012.All total and free serumPSA levels of the
patients and control subjects were recorded.
Results: There was no significant results in the patients with hemodialysis compared with control
group in terms of the total and free serum PSA levels.
Conclusion: Total and free serum PSA levels were not influenced by hemodialysis application

Keywords

• Chronic renal failure
• hemodialysis
• prostate spesific antigen

HEMODİYALİZ HASTALARINDA TOTAL VE SERBEST PSA DÜZEYLERİNİN ARAŞTIRILMASI

Abstract

Amaç: Kronik böbrek yetmezliği olan hastalarda hemodiyaliz uygulamasının serum total ve serbest prostat spesifik antijen (PSA) düzeyleri üzerindeki etkisini araştırmaktır.

Gereç ve Yöntem: Çalışmaya Ocak 2011-Mart 2012 tarihleri arasında kronik böbrek yetmezliği nedeniyle hemodiyaliz yapılan 35 hasta ve kontrol grubu olarak da prostat kanseri taraması amacıyla

PSA araştırılan 35 sağlıklı birey dâhil edildi. Hastaların ve kontrol grubunun total ve serbest serum PSA düzeyleri kaydedildi.

Bulgular: Hemodiyaliz uygulanan hastalarda total ve serbest serum PSA düzeyi kontrol grubuna göre istatistiksel olarak anlamlı bulunmadı.

Sonuç: Hemodiyaliz uygulamasının total ve serbest serum PSA düzeylerini etkilemediği belirlendi.

Keywords

• Kronik böbrek yetmezliği
• Hemodiyaliz
• Prostat spesifik antijen

References

1. Ponticelli C. Oncology and the kidney. In Oxford Textbook of Clinical Nephrology, Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls EG (eds), Oxford, 1998, 2752.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1997. CA Cancer J Clin. 1997; : 5-27.
3. Catalona WJ, Smith DS, Ratliff TL, Dodds AM, Coplen DE, Wuan JJ, Petros JA, Andrio-le GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324: 1156-61.
4. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194:755-63.
5. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1- antichymotrypsin. Clin Chem. 1991; 37:1618-25.
6. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate- specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51:222-6.
7. Kilic S, Yalcinkaya S, Guntekin E, Kukul E, Deger N, Sevuk M. Determination of the site of metabolism of total, free, and complexed prostate-specific antigen. Urology 1998; 52:470-3
8. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate specific antigen is metabolized in the liver. J Urol. 1996; 155:1332-5.

9. Wada Y, Nakanishi J, Takahashi W, Kai N, Nakayama Y, Yamashita Y, Honda J, Ueda S. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study. BJU Int. 2006; 98(4):794-7.
10. Horinaga M, Kitamura K, Saito S, Ukimura O, Nakanoma T, Okihara K, Kitagawa M, Nakanishi H, Miki T.Prostate cancer screening with prostate-specific antigen in hemodialysis patients. Urol Int. 2007; 78(4):334-7.
11. Özer G, Koçak B Altınel M, Altan ŞA, Gönenç F. Kronik Böbrek Yetmezliği Ve Hemodiyalizin Serum tPSA, sPSA ve s/tPSA Düzeylerine Etkisi. Türk Üroloji Dergisi. 2001; (4): 498-502.
12. Danişman A, Kiliç S, Kukul E, Yakupoğlu G, Güntekin E, Baykara M, Sevük M. Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen? Eur Urol. 2000; 37(5):579-81.
13. Sumura M, Yokogi H, Beppu M, Honda H. Diagnostic value of serum prostate-specific antigen in hemodialysis patients. Int J Urol. 2003; 10(5):247-50.
14. Bruun L, Björk T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003; 18(3):598-602.
15. Douville P, Tiberi M. Effect of terminal renal failure on the ratio of free to total prostate- specific antigen. Tumour Biol. 1998; 19(2):113-7.